Predictive biomarkers for immunotherapy, including PD-L1 expression, MMR status, TMB, as well as aggressive tumor biology, higher T-lymphocyte infiltration, and inflamed tumor microenvironment, are associated with response to immunotherapy [53,166]. The gene discussed is CD274; the disease is neoplasm.